BEIGF:OTCMKTS
BeOne Medicines
$ 21.95
0.00%
(0.00) 1D
6-р сарын 9, 12:49:46 (GMT-4) · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BEIGF...
Mkt. cap
44.30 тэрбум
Avg. vol.
0.00
Volume
0.00
52-wk high
$ 24.92
52-wk low
$ 21.95
Beta
0.84
Shares outstanding
1.43 тэрбум
No. of employees
12 мян
Mkt. cap
44.30 тэрбум
Avg. vol.
0.00
Volume
0.00
52-wk high
$ 24.92
52-wk low
$ 21.95
Beta
0.84
Shares outstanding
1.43 тэрбум
No. of employees
12 мян
News stories
From web sources and news partners
TipRanks
·
14 цагийн өмнө
BeOne Medicines Grants New RSUs to 277 Employees Under Incentive Plan
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 мян
Founded2010 оны 10-р сарын 28
Headquarters-
Sector-
Websitebeonemedicines.com